Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Oxytetracycline Dihydrate: adverse event reports

All products with this active ingredient · 3 FDA-approved applications in the Green Book

220reports naming this ingredient, 2012–20260% of all reports · about 17 a year
14reports, 12 months to March 202616 in the 12 months before
65.6%classed serious, as reportedof 125 reports stating it
24.5%record death or euthanasia, as reported54 reports
40%of reports concern cattle0.3% of all cattle reports

FDA has received 220 adverse event reports in which a drug is recorded with oxytetracycline dihydrate as its active ingredient, from December 2012 to January 2026. The Green Book lists 3 FDA-approved applications with this single active ingredient.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 14 reports named it, down 12% from 16 in the 12 months before. Recent months are provisional: fDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 17 reports a year and 0% of all 1,357,245 reports (0.3% of all cattle reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

Reporters most often listed vials, Damaged (23.6%), death (20%) and lack of efficacy - NOS (7.3%). A report can list several signs, so shares add to more than 100%; 174 different terms appear across these reports. Vials, Damaged appears in 23.6% of these reports, a larger share than in the pooled reports for every drug containing oxytetracycline dihydrate (13.7%).

40% of reports concern cattle. Not every report describes illness: 10.5% were filed wholly or partly as lack of expected effectiveness and 43.6% as product or packaging defects. Of reports that state seriousness, 65.6% were classed as serious, and 24.5% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog4 · peak 1
Oct 2021: 1May 2022: 1Mar 2023: 1Apr 2023: 12022202320242025
Cat1 · peak 1
Nov 2024: 12022202320242025
Horse6 · peak 2
Jun 2021: 1Apr 2022: 2Nov 2022: 1Dec 2022: 1Oct 2025: 12022202320242025
Other93 · peak 6
Apr 2021: 1May 2021: 1Jun 2021: 2Jul 2021: 1Aug 2021: 4Sep 2021: 1Oct 2021: 3Nov 2021: 3Dec 2021: 2Jan 2022: 3Feb 2022: 1Mar 2022: 1May 2022: 2Jun 2022: 1Jul 2022: 3Aug 2022: 2Sep 2022: 1Oct 2022: 4Nov 2022: 4Dec 2022: 2Jan 2023: 4Feb 2023: 2Mar 2023: 2Apr 2023: 1Jun 2023: 1Jul 2023: 2Aug 2023: 2Oct 2023: 1Nov 2023: 1Dec 2023: 2Jan 2024: 2Feb 2024: 3May 2024: 2Jul 2024: 6Aug 2024: 2Sep 2024: 1Oct 2024: 1Nov 2024: 2Feb 2025: 1Apr 2025: 2May 2025: 1Jul 2025: 1Sep 2025: 1Oct 2025: 2Nov 2025: 3Jan 2026: 32022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

021422012: 120122013: 320132014: 220142015: 320152016: 220162017: 820172018: 1620182019: 4220192020: 3420202021: 2520212022: 2920222023: 2020232024: 2020242025: 1220252026: 32026

2026 covers reports received through March 2026 only.

Signs listed in reports

share of oxytetracycline dihydrate reports listing the termall drugs containing oxytetracycline dihydrateall cattle reports

  1. Vials, Damaged[a product quality report, not a sign in an animal]23.6%52
  2. Death20%44
  3. Lack of efficacy - NOS[the product did not have the expected effect]7.3%16
  4. Bottles, Damaged[a product quality report, not a sign in an animal]6.8%15
  5. Injection site swelling[swelling where the injection was given]6.8%15
  6. Anaphylaxis[sudden severe allergic-type reaction]5.9%13
  7. Appearance, Abnormal[a product quality report, not a sign in an animal]4.1%9
  8. Containers, Leaking[a product quality report, not a sign in an animal]4.1%9
  9. Lack of efficacy (bacteria) - NOS[the product did not have the expected effect: target not specified]3.2%7
  10. Product Defect, General[a product quality report, not a sign in an animal]3.2%7
  11. Accidental exposure[exposure that was not intended]2.7%6
  12. Collapse NOS[NOS: not otherwise specified]2.7%6
  13. Color, Abnormal[a product quality report, not a sign in an animal]2.7%6
  14. Behavioural disorder NOS[behaviour change, type not specified]2.3%5
  15. Death by euthanasia[the animal was euthanized]2.3%5
  16. Anorexia[not eating]1.8%4
  17. Containers, Damaged[a product quality report, not a sign in an animal]1.8%4
  18. Injection site bleeding[bleeding where the injection was given]1.8%4
  19. Injection site inflammation[inflammation where the injection was given]1.8%4
  20. Injection site pain[pain where the injection was given]1.8%4
  21. Defect Unknown/Not Specified[a product quality report, not a sign in an animal]1.4%3
  22. Hyperthermia[raised body temperature]1.4%3
  23. Ineffective, antibiotic[legacy FDA term: the product did not have the expected effect (antibiotic)]1.4%3

Top 30 of 174 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal19.1%42
Recovered with Sequela0.5%1
Ongoing3.2%7
Died22.3%49
Euthanized2.3%5
Outcome Unknown18.6%41

What kind of report it was

Safety issue45.9%101
Lack of expected effectiveness8.2%18
Both safety and lack of expected effectiveness2.3%5
Manufacturing or product defect43.6%96
Other0%0

Coloured bar: reports naming oxytetracycline dihydrate. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Cattle40%88
Human exposure6.8%15
Horse4.5%10
Dog3.2%7
Goat1.4%3
Cat0.5%1

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year12.7%28
1 to 3 years13.6%30
4 to 7 years2.7%6
8 to 11 years2.7%6
12 years and over8.2%18
Age not given60%132

Weight of the animal

Under 5 kg (11 lb)0.9%2
5 to 9.9 kg (11–22 lb)1.4%3
10 to 24.9 kg (22–55 lb)1.4%3
25 to 44.9 kg (55–99 lb)0%0
45 kg and over (99 lb+)36.4%80
Weight not given60%132

Route of administration stated in reports: subcutaneous (40), intramuscular (26), intravenous (6), oral (4), parenteral (3), cutaneous (1).

In context

MeasureOxytetracycline DihydrateAll drugs containing oxytetracycline dihydrateAll cattle reportsAll reports
Reports22038731,2291,357,245
Share of that pool's reports naming this drug—56.8%0.3%0%
Classed serious, of reports stating it65.6%64.7%58.4%38.6%
Death or euthanasia recorded, per 1,000 reports245.525136863.8
Filed as lack of expected effectiveness (wholly or partly)10.5%——23%
Top term, share of reportsVials, Damaged 23.6%13.7%0%—

The oxytetracycline dihydrate pool is every report naming oxytetracycline dihydrate alone or in any combination; this single-ingredient set accounts for 56.8% of it. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Active ingredientsReportsLatest 12 months
Oxytetracycline + Oxytetracycline Dihydrate1654

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

FDA-approved products containing oxytetracycline dihydrate (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Trade nameActive ingredientsSponsorApproved forApplication
Terramycin 100 for Fish; Terramycin 200 for FishOxytetracycline DihydratePhibro Animal Health Corp.—NADA 038-439
Noromycin 300 LAOxytetracycline DihydrateNorbrook Laboratories, Ltd.Cattle, SwineNADA 141-143
Agrimycin 200Oxytetracycline DihydrateHuvepharma EOODCattle, SwineANADA 200-128

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about oxytetracycline dihydrate reports

How many adverse event reports has FDA received for oxytetracycline dihydrate?

220 reports record a drug with oxytetracycline dihydrate as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 14 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 3 approved applications with this ingredient alone; the reference list on this page names them without any counts.

What signs are reported most often?

vials, Damaged (23.6%), death (20%), lack of efficacy - NOS (7.3%), bottles, Damaged (6.8%) and injection site swelling (6.8%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

cattle (40%), human exposure (6.8%) and horse (4.5%). Among single-breed animals the most frequent labels are Aberdeen Angus, Hereford cattle, Holstein-Friesian and Red Angus; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

14 reports in the 12 months to March 2026, down 12% from 16 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that oxytetracycline dihydrate harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of oxytetracycline dihydrate?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.